Carotid Revascularization With MicroNet Covered Stent Comparing Early Neurological Outcomes With Distal Versus Proximal EPS

Recruiting N/A Interventional Study
Patients With Aterosclerotic Carotid Stenosis Symptomatic Patients (Stenosis > 50%) Asymptomatic Patients (Stenosis ≥80%)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
45 – 80
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
366 (estimated)
Sponsor
Meshalkin Research Institute of Pathology of Circulation · Research network
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence for a difference between the proximal and distal anti-embolic device for the CGuard stent.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria 1. Consecutive patients 45-80 years old accepted for CAS following neurological consultation and qualification for the procedure according to center's routine practice. 2. More than 6-month life expectancy 3. Suitable clinical conditions for performing DW-MRI 4. Written Informed …
Contacts

Andrey A Kaprenko, MD

+79139504100

a_karpenko@meshalkin.ru

CONTACT